Targeted therapy

Candidates for targeted therapy are patients whose tumors have been identified with specific molecular abnormalities, such as gene mutations or overexpressed receptors. Targeted therapy is commonly used in cancers like breast cancer, lung cancer, colorectal cancer, melanoma, and some forms of leukemia and lymphoma. Before starting therapy, doctors will conduct genetic testing or molecular profiling to determine the presence of targets that the therapy can act upon.

Preparation for targeted therapy involves diagnostic tests that identify the specific molecular characteristics of the tumor. Patients may have a sample of tumor tissue or blood taken for molecular analysis. These tests allow doctors to select the most effective drug for the patient based on the molecular targets present.

Meeting with the doctor before starting targeted therapy involves a detailed explanation of how the therapy will work, what potential side effects may occur, and how long the therapy will last. The doctor will also discuss how the effectiveness of the therapy will be monitored and what options are available if the therapy is not effective.

Results of targeted therapy can be very effective, especially if the tumor has specific molecular targets that the therapy can block. For some patients, targeted therapy can significantly reduce tumor size or slow its progression. However, it is possible that over time the tumor may develop resistance to the therapy, which may require a change in treatment approach.

Precautions during targeted therapy include careful monitoring of potential side effects, which may involve issues with the skin, digestive system, liver, or blood pressure. Patients should remain in close contact with their doctor to promptly identify and manage any side effects. It is also important to regularly undergo follow-up examinations to monitor the effectiveness of the therapy and adjust the treatment strategy as needed.